Recovery from metabolic syndrome reduces CV risk

  • Park S & al.
  • Ann Intern Med
  • 26 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A study of 10 million people found that recovering from metabolic syndrome (MetS) is tied to decreased risk for major adverse cardiovascular (CV) events (MACEs).

Why this matters

  • These authors say that the results offer hope to patients with MetS that getting treatment for its 5 factors can lead to decreased MACE risk.
  • This study compared outcomes for people who develop vs people who recover from MetS vs other studies of people with and without MetS.

Key results

  • MACE incidence rates:
    • Chronic MetS: 8.52/1000 person-years.
    • Developed MetS: 6.05/1000 person-years.
    • Recovered from MetS: 4.55/1000 person-years.
    • No MetS: 1.92/1000 person-years.
  • At a median of 3.54 years:
    • With MetS recovery, MACE risk (adjusted incidence rate ratio [IRR]) was 0.85 (95% CI, 0.83-0.87) vs chronic MetS.
    • In those who developed MetS, adjusted IRR for MACE risk was 1.36 (95% CI, 1.33-1.39) vs having no MetS.
  • Hypertension drove much of the change in MACE risk.

Study design

  • National database study, Korea, covering 9,553,042 people ages 20+ years with health insurance and no MACE history, 2009-2014.
  • Funding: Republic of Korea.

Limitations

  • Limited assessment of mortality, short follow-up, retrospective.